Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy
Authors: Milotay Gusztav , Little Martin , Watson Robert , Muldoon Dylan , Tong Orion , Taylor Chelsea , MacKay Sophie , Nassiri Isar , Sun Bo , Webb Louisa M , Bremke Julia , Akin-Adigun Oluwafemi , Sharma Piyush Kumar , Ye Weiyu , Cooper Ros , Danielli Sara , Santo Flavia Matos , de Los Aires Alba Verge , Gilchrist James , Ng Esther , Chong Amanda Y , Mentzer Alex , Youdell Michael , Woodcock Victoria , Coupe Nicholas , Payne Miranda J , Klenerman Paul , Middleton Mark M , Fairfax Benjamin P 
Published: October 2024

Summary ParagraphThe relationship between chronic viral infection and cancer response to immune checkpoint blockade (ICB) is poorly understood. Cytomegalovirus (CMV) infection is globally endemic and causes severe disease in the immunocompromised. In immunocompetent individuals the clinical effects of CMV infection are an area of active investigation. Here, in analysis of 396 patients receiving ICB for cancer, we investigate the oncological and immunological consequences of CMV seropositivity. We find that infection with CMV leads to profound skewing of CD8+T cell subsets towards an effector phenotype, divergence in gene expression, increased total lymphocyte count and reduced neutrophil:lymphocyte ratio. These differences are associated with immunologically distinct responses to ICB in patients with metastatic melanoma (MM). We identify a gene set highly-associated with CMV infection which is robustly induced by combination ICB (anti-CTLA-4 + anti-PD-1, cICB) but not by single-agent anti-PD-1 (sICB) in CMV seronegative individuals. Consequently, CMV seropositivity is associated with prolonged Overall Survival (OS) in those treated with sICB (HR 0.49, P.01) whereas there is no observed survival association of CMV following cICB treatment (HR 0.95, P=.82). We demon-strate these CMV-determined divergent effects are driven by expression ofTBX21, encoding the transcription factor T-bet. Expression ofTBX21predicts OS across all patients (HR 0.67, P=0.013 for above-median expression), with durable response to ICB associated with induction of expandedTBX21expressing CD8+clones. Unexpectedly, we find CMV infection is associated with reduced cumulative incidence of Grade 3+ immune related adverse events (irAEs) at 6 months (0.31 vs. 0.53, P=2.1×10−5), notably lowering incidence of colitis (P=.00095) and pneumonitis (P=.026), with infected patients requiring fewer steroids or second line immunosuppressants. Finally we link CMV infection to protection against MM, demonstrating lower seropositivity rates in patients with MM, but not early Stage II/III disease, compared to population controls from the UK biobank (OR 0.53, P=.00016). CMV protection is contingent upon melanomaBRAFmutation status, with CMV being associated with reduced development of MM inBRAFmutated patients and later presentation ofBRAFwild-type MM.This work reveals a previously unrecognised interaction between CMV infection, melanoma muta-tional state, development of metastatic disease and response to ICB, as well as demonstrating CMV infection protects against ICB irAEs, underpinning the importance of prior infection history and chronic immune activation in development of MM and outcomes to immunotherapy. We anticipate other immunosensitive cancers may show similar interactions between chronic viral infection and response to ICB.